Legal Writing Simplified: Grammarly For Civil Disputes And Demand Letters

A proposed legal-writing tool would verify citations and format demand letters and civil filings for self-represented litigants.

California Attorney General Cancels Paramount Settlement Talks Over $111 Billion Warner Bros. Discovery Deal, Says He’ll Meet When They ‘Stop Playing Games’

California Attorney General cancels negotiations with Paramount over a $111 billion Warner Bros. Discovery deal, citing frustration and plans to meet when negotiations improve.

US-Zölle: US-Konzerne Fordern Neue Verhandlungen Mit Kanada

Major US firms urge the Biden administration to reopen negotiations with Canada over tariffs impacting cross-border trade.

Rosen Law Firm Encourages Barclays PLC Investors To Inquire About Securities Class Action Investigation – BCS

Rosen Law Firm encourages Barclays PLC investors to contact them regarding a potential securities class action investigation, details remain under review.

CPKC And IBEW Agree To Binding Arbitration Ending Strike

Canadian Pacific Kansas City and IBEW agree to binding arbitration, ending the strike that affected rail operations. Details on next steps follow.

Sanktionen: Russland

FINMA imposes new sanctions on Russian entities, marking a significant escalation in financial restrictions amid ongoing geopolitical tensions.

JPMorgan Debanked Polymarket

JPMorgan has reportedly debanked Polymarket, a decentralized prediction market platform, raising questions about banking access for crypto-related firms.

The Game-Changing Cyber Capabilities Of GLM-5.3 AI

Z.ai’s GLM-5.3, launched on August 14, 2026, demonstrates significant improvements in coding and cybersecurity, but its rapid capability growth raises safety concerns.

Turutegemise Lepingu Sõlmimine

Ettevõte sõlmis olulise turutegemise lepingu, mis võib mõjutada aktsiaturu liikumisi. Detailid on veel piiratud, arengud jälgitakse edasi.

The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than A One-Drug Biotech

NeOnc’s extensive patent holdings may enable NTHI to develop multiple drugs, beyond its current one-drug focus, potentially transforming its biotech prospects.